Team
Team

Julia Hardick, M.Sc.

Position: PhD Student

Room no.: CP-02-110

Telephone no.: +49 231 755 7053

Member of the group since: 11/2015

University degree: M.Sc. in Chemical Biology, TU Dortmund University

 

Expertise: organic synthesis, pharmacokinetics (drug metabolism studies)

Off-Lab activities (hobbies): badminton, inline skating

Research projects:

The research project contains structure-based design, organic synthesis and the determination of synthesized compounds in a pharmacokinetic context, such as the identification of metabolic stability in a phase I metabolism assay as well as plasma stability.
Regarding the synthesis part of my work I focused on Her2, a member of the human epidermal growth factor receptor family, which overexpression has been shown to act as a key player in breast cancer. A second synthesis project deals with the mitogen activated protein kinase kinase 7 (MKK7) and the evaluation of covalent inhibitors to target the JNK-pathway. Both kinases represent attractive targets in drug discovery and offer fascinating medicinal chemistry projects.

 

Earlier Positions:

Bachelor and master studies in the group of Daniel Rauh on the MAPK p38α

 

Publications:

  1. Lategahn, J.; Hardick, J.; Grabe, T.; Niggenaber, J.; Jeyakumar, K.; Keul, M.; Tumbrink, H. L.; Becker, C.; Hodson, L.; Kirschner, T.; Klövekorn, P.; Ketzer, J.; Baumann, M.; Terheyden, S.; Unger, A.; Weisner, J.; Müller, M. P.; van Otterlo, W. A. L.; Bauer, S.; Rauh, D.. Targeting Her2-insYVMA with Covalent Inhibitors-A Focused Compound Screening and Structure-Based Design Approach. J. Med. Chem. 2020, 63 (20), 11725–11755.

    DOI PubMed

  2. Niggenaber, J.; Hardick, J.; Lategahn, J.; Rauh, D.. Structure Defines Function: Clinically Relevant Mutations in ErbB Kinases. J. Med. Chem. 2020, 63 (1), 40–51.

    DOI PubMed

  3. Lategahn, J.; Keul, M.; Klövekorn, P.; Tumbrink, H. L.; Niggenaber, J.; Müller, M. P.; Hodson, L.; Flaßhoff, M.; Hardick, J.; Grabe, T.; Engel, J.; Schultz-Fademrecht, C.; Baumann, M.; Ketzer, J.; Mühlenberg, T.; Hiller, W.; Günther, G.; Unger, A.; Müller, H.; Heimsoeth, A.; Golz, C; Blank-Landeshammer, B.; Kollipara, L.; Zahedi, R. P.; Strohmann, C.; Hengstler, J. G.; van Otterlo, W. A. L.; Bauer, S.; Rauh, D.. Inhibition of osimertinib-resistant epidermal growth factor receptor EGFR-T790M/C797S. Chem. Sci. 2019, 10 (46), 10789–10801.

    DOI PubMed

  4. Uhlenbrock, N.; Smith, S.; Weisner, J.; Landel, I.; Lindemann, M.; Le, T. A.; Hardick, J.; Gontla, R.; Scheinpflug, R.; Czodrowski, P.; Janning, P.; Depta, L.; Quambusch, L.; Müller, M. P.; Engels, B.; Rauh, D.. Structural and chemical insights into the covalent-allosteric inhibition of the protein kinase Akt. Chem. Sci. 2019, 10 (12), 3573–3585.

    DOI PubMed

  5. Weisner, J.; Landel, I.; Reintjes, C.; Uhlenbrock, N.; Trajkovic-Arsic, M.; Dienstbier, N.; Hardick, J.; Ladigan, S.; Lindemann, M.; Smith, S.; Quambusch, L.; Scheinpflug, R.; Depta, L.; Gontla, R.; Unger, A.; Müller, H.; Baumann, M.; Schultz-Fademrecht, C.; Günther, G.; Maghnouj, A.; Müller, M. P.; Pohl, M.; Teschendorf, C.; Wolters, H.; Viebahn, R.; Tannapfel, A.; Uhl, W.; Hengstler, J. G.; Hahn, S. A.; Siveke, J. T.; Rauh, D.. Preclinical Efficacy of Covalent-Allosteric AKT Inhibitor Borussertib in Combination with Trametinib in KRAS-Mutant Pancreatic and Colorectal Cancer. Cancer Res. 2019, 79 (9), 2367–2378.

    DOI PubMed

  6. Wolle, P.; Hardick, J.; Cronin, S. J. F.; Engel, J.; Baumann, M.; Lategahn, J.; Penninger, J. M.; Rauh, D.. Targeting the MKK7-JNK (Mitogen-Activated Protein Kinase Kinase 7-c-Jun N-Terminal Kinase) Pathway with Covalent Inhibitors. J. Med. Chem. 2019, 62 (5), 2843–2848.

    DOI PubMed

  7. a) Bührmann, M.; Hardick, J.; Weisner, J.; Quambusch, L.; Rauh, D.. Covalent Lipid Pocket Ligands Targeting p38α MAPK Mutants. Angew. Chem. Int. Ed. Engl. 2017, 56 (43), 13232–13236.

    DOI PubMed

    b) Bührmann, M.; Hardick, J.; Weisner, J.; Quambusch, L.; Rauh, D.. Kovalente Liganden zur Adressierung einer lipophilen Bindetasche in der MAPK p38 α. Angew. Chem. 2017, 129 (43), 13415–13419.

    DOI

  8. Bührmann, M.; Wiedemann, B. M.; Müller, M. P.; Hardick, J.; Ecke, M.; Rauh, D.. Structure-based design, synthesis and crystallization of 2-arylquinazolines as lipid pocket ligands of p38α MAPK. PLoS One 2017, 12 (9), e0184627.

    DOI PubMed

  9. Kaitsiotou, H.; Keul, M.; Hardick, J.; Mühlenberg, T.; Ketzer, J.; Ehrt, C.; Krüll, J.; Medda, F.; Koch, O.; Giordanetto, F.; Bauer, S.; Rauh, D.. Inhibitors to Overcome Secondary Mutations in the Stem Cell Factor Receptor KIT. J. Med. Chem. 2017, 60 (21), 8801–8815.

    DOI PubMed